Drugs for Pulmonary Hypertension, Primary, 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 325)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Epoprostenol |
Approved |
Phase 4 |
|
61849-14-7, 35121-78-9 |
5282411 |
Synonyms:
(5Z,13E)-(15S)-6,9a-Epoxy-11a,15-dihydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-6,9a-Epoxy-11a,15-dihydroxyprosta-5,13-dienoic acid
(5Z,13E)-(15S)-6,9alpha-Epoxy-11alpha,15-dihydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-6,9-alpha-Epoxy-11-alpha,15-dihydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-6,9alpha-Epoxy-11alpha,15-dihydroxyprosta-5,13-dienoic acid
(5Z,13E)-(15S)-6,9-alpha-Epoxy-11-alpha,15-dihydroxyprosta-5,13-dienoic acid
(5Z,13E)-(15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dienoic acid
(5Z,13E)-(15S)-6,9Α-epoxy-11α,15-dihydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-6,9Α-epoxy-11α,15-dihydroxyprosta-5,13-dienoic acid
(5Z,13E,15S)-6,9a-Epoxy-11a,15-dihydroxyprosta-5,13-dienoate
(5Z,13E,15S)-6,9a-Epoxy-11a,15-dihydroxyprosta-5,13-dienoic acid
(5Z,9a,11a,13E,15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dien-1-Oate
(5Z,9a,11a,13E,15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dien-1-Oic acid
(5Z,9alpha,11alpha,13E,15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dien-1-Oate
(5Z,9alpha,11alpha,13E,15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dien-1-Oic acid
(5Z,9Α,11α,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-Oate
(5Z,9Α,11α,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-Oic acid
ACT-385781A
Epoprostanol
|
Epoprostenol
EPOPROSTENOL SODIUM
Epoprostenol sodium salt, (5Z,9alpha,11alpha,13E,15S)-isomer
EPOPROSTENOLSODIUM
FLOLAN
PGI2
PG-I2
PGX
Prostacyclin
PROSTACYCLIN SODIUM SALT
prostacyclin|prostacyclin I2|prostaglandin I2|vasocyclin
Prostacycline
Prostaglandin I(2)
PROSTAGLANDIN I2
Prostaglandin X
U-53217
U-53217A
Vasocyclin
VELETRI
|
|
2 |
|
Silver sulfadiazine |
Approved, Vet_approved |
Phase 4 |
|
22199-08-2 |
441244 |
Synonyms:
FLAMAZINE
FLAMMACERIUM
SILDAFLO
SILVADENE
SILVER SULFADIAZINATE
SILVER SULFADIAZINE
SILVER SULPHADIAZINE
|
SSD
SSD AF
SULFADIAZINE SILVER
SULFADIAZINE SILVER SALT
SULFADIAZINE, SILVER
THERMAZENE
|
|
3 |
|
Racepinephrine |
Approved, Vet_approved |
Phase 4 |
|
51-43-4, 329-65-7 |
838 5816 |
Synonyms:
(−)-(R)-epinephrine
(-)-(R)-Epinephrine
(-)-3,4-Dihydroxy-a-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-a-[(methylamino)methyl]-benzyl alcohol
(-)-3,4-Dihydroxy-a-[2-(methylamino)ethyl]benzyl alcohol
(-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-alpha-[(methylamino)methyl]-benzyl alcohol
(-)-3,4-DIHYDROXY-ALPHA-[(METHYLAMINO)METHYL]BENZYL ALCOHOL(-)-3,4-DIHYDROXY-ALPHA-[(METHYLAMINO)METHYL]-BENZYL ALCOHOL
(-)-3,4-Dihydroxy-alpha-[2-(methylamino)ethyl]benzyl alcohol
(−)-3,4-dihydroxy-α-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-α-((methylamino)methyl)benzyl alcohol
(-)-Adrenaline
(−)-ADRENALINE
(-)-Epinephrine
(+-)-Adrenaline
(+-)-Epinephrine
(R)-(-)-Adnephrine
(R)-(-)-Adrenaline
(R)-(−)-ADRENALINE
(R)-(-)-Epinephrine
(R)-(-)-Epirenamine
(R)-4-[1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
(R)-Adrenaline
(R)-Epinephrine
2-(Methylamino)-1-(3,4-dihydroxyphenyl)ethanol
4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
4-[(1R)-1-HYDROXY-2-METHYLAMINOETHYL]BENZENE-1,2-DIOL
4-[(1R)-1-HYDROXY-2-METHYLAMINO-ETHYL]BENZENE-1,2-DIOL
4-[(1R)-1-HYDROXY-2-METHYLAMINO-ETHYL]PYROCATECHOL
Acetate, epinephrine
Adnephrine
ADREN CO
ADRENACLICK
Adrenal
Adrenalin
adrenalin|Auvi-Q®|Epipen®|l-adrenaline|L-epinephrine|levoepinephrine
Adrenaline
Adrénaline
Adrenaline acid tartrate
Adrenaline bitartrate
Adrenaline hydrochloride
Adrenaline hydrochloride, racemic mixture
Adrenaline, racemic
Adrenaline, racemic mixture
adrenaline|epinephrine
Adrenine
Adrin
Allergan brand OF adrenaline hydrochloride
ANA-GUARD
Ana-kit
ANAPEN
ANAPHYLACTIC SHOCK DRUG KIT
ASMA-VYDRIN
ASTHMAHALER
Auvi-Q
Bird brand OF racepinefrine hydrochloride
Bosmin
Bronkaid mist
BROVON
Chelafrin
DL-Adrenaline
EMERADE
EPI E Z PEN JR
Epifrin
Epiglaufrin
Epinefrin
Epinefrina
Epinephran
Epinephrin
EPINEPHRINE
Epinephrine acetate
Epinephrine bitartrate
EPINEPHRINE HCL
Epinephrine hydrochloride
Epinephrine hydrochloride, racemic mixture
Epinephrine hydrogen tartrate
Epinephrine racemic
Epinephrine, racemic
Epinephrine, racemic mixture
Epinephrinum
Epipen
|
EPIPEN E Z PEN
Epipen JR
EPIPEN JR.
Epirenan
Epitrate
Eppy
Exadrin
Glauposine
GPPE INH SOLN
Hemisine
Hemostasin
Hemostatin
Hydrochloride, racepinephrine
Hypernephrin
Isoptoepinal
JEXT
L-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
L-Adrenaline
L-DETHYLAMINOETHANOLCATECHOL
L-Epinephrine
L-Epirenamine
Levoepinephrine
LEVO-METHYLAMINOETHANOLCATECHOL
Levorenen
Levorenin
Levorenine
Levoreninum
L-Methylaminoethanolcatechol
Lyodrin
Lyophrin
Medihaler-epi
Methylarterenol
Micronefrin
Micronephrine
Mixture adrenaline, racemic
Mixture epinephrine, racemic
Mucidrina
Nephridine
Nieraline
NSC-62786
Paranephrin
Primatene
Primatene mist
R-(-)-Epinephrine
Racemic adrenaline
Racemic epinephrine
Racemic mixture adrenaline
Racemic mixture epinephrine
Racepinefrina
Racepinefrine
Racepinefrinum
Racepinephrine
Racepinephrine hydrochloride
Renaglandin
Renaleptine
Renalina
Renoform
Renostypticin
Renostyptin
RIDDOBRON
RIDDOFAN
RYBARVIN
Scurenaline
Simplene
SOLN MADE TO RYBARVIN FOR
Styptirenal
Supracapsulin
Supranephrane
Suprarenaline
Suprarenin
Surrenine
Sus-phrine
SUS-PHRINE SULFITE FREE
SUS-PHRINE SULFITE-FREE
SYMJEPI
Takamina
TWINJECT
TWINJECT 0.15
TWINJECT 0.3
Vaponefrin
Vasoconstrictine
Vasotonin
|
|
4 |
|
Racephedrine |
Approved, Experimental |
Phase 4 |
|
299-42-3, 90-82-4, 90-81-3 |
5032 9294 7028 |
Synonyms:
(-)-Ephedrine
(+) Threo-2-(methylamino)-1-phenyl-1-propanol
(+)-(1S,2S)-Pseudoephedrine
(+-)-Ephedrine
(+)-Pseudoephedrine
(+)-Psi-ephedrine
(+)-Threo-ephedrine
(1R,2S)-1-Phenyl-1-hydroxy-2-methylaminopropane
(1S,2S)-(+)-Pseudoephedrine
(1S,2S)-Pseudoephedrine
1-Ephedrine
2-(Methylamino)-1-phenyl-1-propanol
Acunaso
Besan
D-Isoephedrine
D-Pseudoephedrine
D-Pseudoephedrine base
D-Psi-2-methylamino-1-phenyl-1-propanol
D-Psi-ephedrine
Efedrina
Emerphed® (ephedrine sulfate injection)
Ephedrine
Ephedrine DL-form
Ephedrine erythro isomer
Ephedrine hydrochloride
Ephedrine renaudin
Ephedrine sulfate
Ephedrine threo isomer
Erythro isomer OF ephedrine
Hydrochloride, ephedrine
Isoephedrine
L(-)-Ephedrine
L(−)-EPHEDRINE
|
L-(+)-Pseudoephedrine
L(+)-Psi-ephedrine
L-Ephedrine
L-Erythro-2-(methylamino)-1-phenylpropan-1-ol
Neodurasina
Novafed
NSC-170951
NSC-8971
Pseudoefedrina
Pseudoephedrine
pseudoéphédrine
Pseudoephedrine D-form
Pseudoephedrine ephedrine
Pseudoephedrine HCL
Pseudoephedrine hydrochloride
Pseudoephedrinum
PSEUDOPHEDRINE SULPHATE
Psi-ephedrin
Psi-ephedrine
Racephedrine
Renaudin brand OF ephedrine hydrochloride
Renaudin, ephedrine
Sal phedrine
Sal-phedrine
SalPhedrine
SINUTAB
Sudafed
Sulfate, ephedrine
Threo isomer OF ephedrine
trans-Ephedrine
Wendt brand OF ephedrine sulfate
ψ-ephedrine
|
|
5 |
|
Phenylephrine |
Approved |
Phase 4 |
|
59-42-7 |
6041 |
Synonyms:
(-)-m-Hydroxy-a-(methylaminomethyl)benzyl alcohol
(-)-m-Hydroxy-alpha-(methylaminomethyl)benzyl alcohol
(−)-m-hydroxy-α-(methylaminomethyl)benzyl alcohol
(-)-m-Hydroxy-α-(methylaminomethyl)benzyl alcohol
(R)-3-[-1-HYDROXY-2-(METHYLAMINO)ETHYL]PHENOL
(R)-3-Hydroxy-alpha-((methylamino)methyl)benzenemethanol
AB-101 (PHENYLEPHRINE)
Adrianol
Ak-dilate
Ak-nefrin
Alcon efrin
Alconefrin nasal drops 12
Alconefrin nasal drops 25
Alconefrin nasal drops 50
Alconefrin nasal spray 25
BENZENEMETHANOL, 3-HYDROXY-.ALPHA.-[(METHYLAMINO)METHYL]-, (R)-
BENZENEMETHANOL, 3-HYDROXY-ALPHA-((METHYLAMINO)METHYL)-, (R)-
BENZYL ALCOHOL, M-HYDROXY-ALPHA-((METHYLAMINO)METHYL)-, (-)-
Biomydrin
CYCLOMYDRIL
Dilatair
Dimetane
Dionephrine
Doktors
DUO-MEDIHALER
Duration
Fenilefrina
Fenilefrina [INN-Spanish]
I-phrine
Isophrim
Isophrin
Isopto frin
J8.601K
L-(3-Hydroxyphenyl)-N-methylethanolamine
L-Phenylephedrine
L-Phenylephrine
Mesaton
Mesatone
Mesatonum
Metaoxedrin
Metaoxedrine
Metaoxedrinum
Metasympatol
Metasynephrine
|
Metsatonum
Mezaton
Minims phenylephrine
m-Methylaminoethanolphenol
m-Oxedrine
m-oxedrine|metasynephrine
m-Sympathol
m-Sympatol
m-Synephrine
Mydfrin
Neo synephrine
Neofrin
Neophryn
Neosynephrine
Neo-synephrine
Neo-synephrine nasal drops
Neo-synephrine nasal jelly
Neo-synephrine nasal spray
Neo-synephrine pediatric nasal drops
Nostril
Nostril spray pump
Nostril spray pump mild
Ocugestrin
Ocu-phrin sterile eye drops
Ocu-phrin sterile ophthalmic solution
PEF100
Phenoptic
PHENYLEPHRINE
Phenylephrine hydrochloride
Phenylephrine minims
Phenylephrine tannate
Phenylephrinum
Phenylephrinum [INN-Latin]
Prefrin
Prefrin liquifilm
Pyracort D
R(-)-Mezaton
R(-)-Phenylephrine
Relief eye drops for red eyes
Rhinall
Spersaphrine
Tannate, phenylephrine
Vicks sinex
Visadron
|
|
6 |
|
Oxymetazoline |
Approved, Investigational |
Phase 4 |
|
1491-59-4 |
4636 |
Synonyms:
2-(4-Tert-butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazoline
3-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethylphenol
6-t-Butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol
6-Tert-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol
Afrin
Afrin®|oxymethazoline|SCH-9384|Upneeq® (opthalmic solution)|Vicks Sinex®
Hydrochloride, oxymetazoline
OCUCLEAR
Operil
Oximetazolinum
|
Oxymetazolina
OXYMETAZOLINE
Oxymétazoline
Oxymetazoline hydrochloride
Oxymetazoline hydrochloride crystalline
Oxymetazolinum
Oxymethazoline
Oxymetozoline
SCH-9384
VICKS SINEX
|
|
7 |
|
Selexipag |
Approved |
Phase 4 |
|
475086-01-2 |
9913767 |
Synonyms:
2-(4-((5,6-Diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)-N-(methylsulfonyl)acetamide
ACT 293987
ACT-293987
ACT-293987|NS-304|Uptravi®
|
NS 304
NS-304
Selexipag
Uptravi
|
|
8 |
|
Riociguat |
Approved |
Phase 4 |
|
625115-55-1 |
11304743 |
Synonyms:
Adempas
Adempas®|BAY 63-2521
BAY 63-2521
BAY-63-2521
Methyl N-(4,6-diamino-2-{1-((2-fluorophenyl)methyl)-1H-pyrazolo(3,4-b)pyridin-3-yl}pyrimidin-5-yl)-N-methylcarbamate
|
Methyl N-(4,6-diamino-2-{1-((2-fluorophenyl)methyl)-1H-pyrazolo(3,4-b)pyridin-3-yl}pyrimidin-5-yl)-N-methylcarbamic acid
METHYL N-[4,6-DIAMINO-2-[1-[(2-FLUOROPHENYL)METHYL]-1H-PYRAZOLO[3,4-B]PYRIDIN-3-YL]-5-PYRIMIDINYL]-N-METHYL-CARBAMINATE
RIOCIGUAT
Riociguatum
|
|
9 |
|
Spironolactone |
Approved |
Phase 4 |
|
1952-01-7, 52-01-7 |
5833 |
Synonyms:
ABBOLACTONE
Acelat
Aldace
Aldactazide
Aldactide
Aldactone
Aldactone a
Aldactone®|spiractin|spirotone
Alderon
Aldopur
Almatol
Alphapharm brand OF spironolactone
Alpharma brand OF spironolactone
Alter brand OF spironolactone
Altex
Aquareduct
Ashbourne brand OF spironolactone
Azupharma brand OF spironolactone
Betapharm brand OF spironolactone
Cardel brand OF spironolactone
CAROSPIR
CT Arzneimittel brand OF spironolactone
CT, Spiro von
CT-Arzneimittel brand OF spironolactone
Deverol
Dexo brand OF spironolactone
DIATENSEC
Dira
Duraspiron
Espironolactona
Espironolactona [INN-Spanish]
Espironolactona alter
Espironolactona mundogen
Euteberol
Flumach
Frumikal
Generosan brand OF spironolactone
GX SPIRONOL
Hormosan brand OF spironolactone
Jenapharm brand OF spironolactone
Jenaspiron
Lacalmin
Lacdene
LARACTONE
Mayoly-spindler brand OF spironolactone
Melarcon
Merck dura brand OF spironolactone
Mundogen brand OF spironolactone
Nefurofan
Novo spiroton
Novopharm brand OF spironolactone
Novo-spiroton
NovoSpiroton
NSC-150399
Osyrol
Pfizer brand OF spironolactone
|
Pharmafrid brand OF spironolactone
Practon
Roche brand OF spironolactone
Sagisal
SC-9420
Searle brand OF spironolactone
Sincomen
SNL
Spiractin
Spiresis
SPIRETIC
Spiridon
SPIRNOLACTONE
Spiro l.u.t.
Spiro von CT
Spirobeta
Spiroctan
SPIROCTAN 100
SPIROCTAN 25
SPIROCTAN 50
Spiroctanie
Spiroderm
Spirogamma
Spirolactone
Spirolakton
Spirolang
Spirolone
Spirone
Spirono isis
Spironocompren
Spirono-isis
SPIRONOLACTONE
Spironolactone [BAN:INN:JAN]
Spironolactone A
Spironolactonum
Spironolactonum [INN-Latin]
Spironolattone
Spironolattone [DCIT]
Spironone
Spirospare
SPIROSPARE 100
SPIROSPARE 25
Spiro-Tablinen
SPIROTONE
Sprioderm
Supra-puren
Suracton
Uractone
Urusonin
Veroshpiron
Verospiron
Verospirone
Verospirone Opianin
Von CT, spiro
Wörwag brand OF spironolactone
Xenalon
|
|
10 |
|
Iloprost |
Approved, Investigational |
Phase 4 |
|
78919-13-8 |
6443959 6435378 5311181 |
Synonyms:
2-oxo-2-Phenylethyl 5-[(2Z)-5-hydroxy-4-[(1E)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]-octahydropentalen-2-ylidene]pentanoic acid
CILOPROST
ILOPROST
Iloprost phenacyl ester
Iloprost-pe
|
VENTAVIS
Ventavis®
ZK-00036374
ZK-36374
|
|
11 |
|
Ambrisentan |
Approved, Investigational |
Phase 4 |
|
177036-94-1 |
6918493 |
Synonyms:
(2S)-2-[(4,6-DIMETHYLPYRIMIDIN-2-YL)OXY]-3-METHOXY- 3,3-DIPHENYLPROPANOIC ACID
AMBRISENTAN
GSK1325760
GSK-1325760
GSK1325760A
|
GSK-1325760A
LETAIRIS
Letairis®
LU-208075
VOLIBRIS
|
|
12 |
|
Macitentan |
Approved |
Phase 4 |
|
441798-33-0 |
16004692 |
Synonyms:
ACT 064992
ACT064992
ACT-064992
ACT-064992|Opsumit®
|
MACITENTAN
Macitentán
MACITENTANUM
OPSUMIT
|
|
13 |
|
Tadalafil |
Approved, Investigational |
Phase 4 |
|
171596-29-5 |
110635 |
Synonyms:
(6R,12AR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R-trans)-6-(1,3-Benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
351, IC
6-BENZO[1,3]dioxol-5-yl-2-methyl-2,3,6,7,12,12a-hexahydro-pyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
Adcirca
Adcirca®|Cialis®|IC-351|IC351
Cialis
|
IC351
IC-351
ICOS 351
Tadalafil
Tadalafilo
Tadanafil
Zalutia
|
|
14 |
|
Tezosentan |
Investigational |
Phase 4 |
|
180384-57-0 |
|
Synonyms:
5-Isopropyl-pyridine-2-sulfonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl--pyridin-4-yl)--pyrimidin-4-ylamide
ACT-050089
RO-610612
|
RO-61-0612
TEZOSENTAN
Veletri
|
|
15 |
|
Beraprost |
Investigational |
Phase 4 |
|
88430-50-6 |
2352 5282428 |
Synonyms:
4-(1,2,3a,8b-Tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyloct-6-yne-1-enyl)-5-cyclopenta(b)benzofuranyl)butyrate
BERAPROST
Beraprost sodium
Beraprostum
MDL 201229|MDL-201229|ML 1229|ML-1229
|
MDL-201229
ML-1229
TRK 100
TRK-100
TRK-100STP FREE ACID
|
|
16 |
|
Vardenafil Dihydrochloride |
|
Phase 4 |
|
|
|
17 |
|
Arginine Vasopressin |
|
Phase 4 |
|
|
|
18 |
|
Vasopressins |
|
Phase 4 |
|
|
|
19 |
|
Platelet Aggregation Inhibitors |
|
Phase 4 |
|
|
|
20 |
|
Epinephryl borate |
|
Phase 4 |
|
|
|
21 |
|
Mydriatics |
|
Phase 4 |
|
|
|
22 |
|
Nasal Decongestants |
|
Phase 4 |
|
|
|
23 |
|
Hormones |
|
Phase 4 |
|
|
|
24 |
|
diuretics |
|
Phase 4 |
|
|
|
25 |
|
Hormone Antagonists |
|
Phase 4 |
|
|
|
26 |
|
Mineralocorticoids |
|
Phase 4 |
|
|
|
27 |
|
Mineralocorticoid Receptor Antagonists |
|
Phase 4 |
|
|
|
28 |
|
Anticoagulants |
|
Phase 4 |
|
|
|
29 |
|
Chelating Agents |
|
Phase 4 |
|
|
|
30 |
|
Endothelin A Receptor Antagonists |
|
Phase 4 |
|
|
|
31 |
|
Liver Extracts |
|
Phase 4 |
|
|
|
32 |
|
Natriuretic Peptide, Brain |
|
Phase 4 |
|
|
|
33 |
|
Benzocaine |
Approved, Investigational |
Phase 3 |
|
1994-09-7, 94-09-7 |
2337 |
Synonyms:
(P-(Ethoxycarbonyl)phenylamine
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-Aminobenzoate
4-Aminobenzoate ethyl ester
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Carbethoxyaniline
Acetate, benzocaine
Aethoform
AEZODENT
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthin
Anestezin
Anesthesin
Anesthesine
Anesthone
ANTHISAN PLUS
AR01
AR-01
Baby anbesol
Bensokain
Benzoak
Benzocaina
BENZOCAINE
Benzocaine acetate
Benzocaine formate
Benzocaine hydrobromide
Benzocaine hydrochloride
Benzocaine methanesulfonate
Benzocainum
BURNEZE
CHILDREN'S CHLORASEPTIC
DEQUACAINE
Dermoplast
Diet ayds
Ethoform
Ethyl 4-aminobenzoate
|
Ethyl 4-aminobenzoic acid
Ethyl aminobenzoate
Ethyl aminobenzoic acid
Ethyl P-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethyl p-aminophenylcarboxylic acid
Ethylester kyseliny P-aminobenzoove
Formate, benzocaine
Hurricaine
Hydrobromide, benzocaine
Hydrochloride, benzocaine
Identhesin
Keloform
LANACANE
MEDILAVE
Methanesulfonate, benzocaine
NESTOSYL
Norcain
Norcaine
NSC-41531
NSC-4688
Orabase-b
Ora-jel
ORAJEL
Orthesin
p-(Ethoxycarbonyl)aniline
P-Aminobenzoate
P-Aminobenzoic acid
P-Aminobenzoic acid ethyl ester
Parathesin
Parathesine
p-Carbethoxyaniline
p-Ethoxycarboxylic aniline
Slim mint gum
Solarcaine
Solu H
Topcaine
TYROSOLVEN
TYROZETS
|
|
34 |
|
Tannic acid |
Approved |
Phase 3 |
|
1401-55-4 |
16129878 16129778 |
Synonyms:
Acid, tannic
ácido tánico
Acids, tannic
E181
FEMA NO. 3042
Gallotannic acid
|
Gallotannin
NSC-656273
TANNIC ACID
Tannic acids
Tannins
|
|
35 |
|
Udenafil |
Approved, Investigational |
Phase 2, Phase 3 |
|
268203-93-6 |
6918523 135413547 |
Synonyms:
3-(1-Methyl-7-oxo-3-propyl-4,7-dihydro-1H-pyrazolo(4,3-D)pyrimidin-5-yl)-N-(2-(1-methyl-2-pyrrolidinyl)ethyl)-4-propoxybenzenesulfonamide
DA-8159
DA-8159|DA8159|Zydena®
|
DA-8159udenafil
UDENAFIL
Zidena
|
|
36 |
|
Trimetazidine |
Approved, Investigational |
Phase 2, Phase 3 |
|
5011-34-7 |
21109 |
Synonyms:
1-[2,3,4-TRIMETHOXYBENZYL] PIPERAZINE DIHYDROCHLORIDE
40045
Alpharma brand OF trimetazidine dihydrochloride
Biopharma brand OF trimetazidine dihydrochloride
Centrophène
Danval brand OF trimetazidine dihydrochloride
Dihydrochloride, trimetazidine
Dilatan
Idaptan
|
Irex brand OF trimetazidine dihydrochloride
Trimetazidina
TRIMETAZIDINE
Trimetazidine dihydrochloride
TRIMETAZIDINE HCL
Trimétazidine irex
Vasartel
Vastarel
VASTAREL MR
|
|
37 |
|
Iodine |
Approved, Investigational |
Phase 3 |
|
7553-56-2 |
807 |
Synonyms:
Cadex
Diiodine
I2
Iode
Iodine
Iodine 127
Iodine-127
Iodine-molecule
|
Iodio
iodo
Iodum
Jod
Jood
Molecular iodine
NSC-42355
Tincture iodine
|
|
38 |
|
Ranolazine |
Approved, Investigational |
Phase 3 |
|
142387-99-3, 95635-55-5 |
56959 |
Synonyms:
(-)-Ranolazine
CVT-303
Dihydrochloride, ranolazine
HCL, Ranolazine
Hydrochloride, ranolazine
N-(2,6-DIMETHYLPHENYL)-2-[4-[2-HYDROXY-3-(2-METHOXYPHENOXY)PROPYL]PIPERAZIN-1-YL]ACETAMIDE
N-(2,6-Dimethylphenyl)-4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)-1-piperazineacetamide
Ranexa
Ranolazina
|
Ranolazine
Ranolazine 2HCL
Ranolazine dihydrochloride
Ranolazine HCL
Ranolazine hydrochloride
Renolazine
RS-43285
RS-43285-003
|
|
39 |
|
Antirheumatic Agents |
|
Phase 2, Phase 3 |
|
|
|
40 |
|
Anti-Inflammatory Agents, Non-Steroidal |
|
Phase 2, Phase 3 |
|
|
|
41 |
|
Analgesics, Non-Narcotic |
|
Phase 2, Phase 3 |
|
|
|
42 |
|
Immunosuppressive Agents |
|
Phase 2, Phase 3 |
|
|
|
43 |
|
Tanshinone |
|
Phase 2, Phase 3 |
|
|
|
44 |
|
Plasma-lyte 148 |
|
Phase 2, Phase 3 |
|
|
|
45 |
|
Imatinib Mesylate |
|
Phase 3 |
|
220127-57-1 |
|
Synonyms:
GLEEVEC
GLIVEC
IMATINIB MESILATE
IMATINIB MESYLATE
|
IMATINIB METHANESULFONATE
STI571
STI-571
|
|
46 |
|
Protein Kinase Inhibitors |
|
Phase 3 |
|
|
|
47 |
|
Protective Agents |
|
Phase 3 |
|
|
|
48 |
|
Bronchodilator Agents |
|
Phase 3 |
|
|
|
49 |
|
Anti-Asthmatic Agents |
|
Phase 3 |
|
|
|
50 |
|
Respiratory System Agents |
|
Phase 3 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 649)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Upfront Riociguat and Ambrisentan Combination Therapy for Pulmonary Arterial Hypertension: A Safety and Efficacy Pilot Study |
Unknown status |
NCT03809156 |
Phase 4 |
Riociguat Oral Product |
2 |
Randomized Controlled Trial to Compare the Efficacy of Combination Therapy vs Monotherapy for Pulmonary Arterial Hypertension in Systemic Sclerosis |
Unknown status |
NCT03053739 |
Phase 4 |
Sildenafil 20mg and Bosentan 62.5mg;Sildenafil 20mg and Placebo |
3 |
Hemodynamic Evaluation of Patients With Pulmonary Arterial Hypertension. Response to Sildenafil Treatment |
Unknown status |
NCT00483626 |
Phase 4 |
oral sildenafil |
4 |
Raising the Bars in the Treatment of Pulmonary Arterial Hypertension: Goal Oriented Strategy to Preserve Ejection Fraction Trial |
Unknown status |
NCT03236818 |
Phase 4 |
ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan) |
5 |
Intravenous Iron Treatment In Iron Deficient Patients With Idiopathic Pulmonary Arterial Hypertension |
Unknown status |
NCT01288651 |
Phase 4 |
Ferricarboxymaltose |
6 |
Effects of Spironolactone on Collagen Metabolism in Pulmonary Arterial Hypertension |
Unknown status |
NCT01468571 |
Phase 4 |
Spironolactone;Placebo |
7 |
Long Acting Phosphodiesterase 5 Inhibitors as Add-on Therapy for Patients With Pulmonary Hypertension Treated With Prostanoids. |
Unknown status |
NCT00705588 |
Phase 4 |
Tadalafil;Vardenafil |
8 |
Vardenafil as add-on Therapy for Patients With Pulmonary Hypertension Treated With Inhaled Iloprost |
Unknown status |
NCT01649739 |
Phase 4 |
Levitra |
9 |
TRACLEER® (Bosentan) Pulmonary Arterial Hypertension A Multicenter, Open-label, Single-arm Safety Study to Investigate the Effects of Chronic TRACLEER® Treatment on Testicular Function in Male Patients With Pulmonary Arterial Hypertension |
Completed |
NCT00082186 |
Phase 4 |
bosentan |
10 |
An Open Label, Single-arm Study Evaluating a New Thermostable Formulation of FLOLANâ„¢ in Japanese Subjects With Pulmonary Arterial Hypertension (PAH) |
Completed |
NCT02705807 |
Phase 4 |
FLOLAN injection with currently marketed diluent;FLOLAN injection with reformulated diluent |
11 |
A Multi-center, Double-blind, Placebo-controlled Phase 4 Study in Patients With Pulmonary Arterial Hypertension to Assess the Effect of Selexipag on Daily Life Physical Activity and Patient's Self-reported Symptoms and Their Impacts |
Completed |
NCT03078907 |
Phase 4 |
Selexipag;Placebo |
12 |
TRUST-2: An Open-label Continuation Trial of the Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH) |
Completed |
NCT03055221 |
Phase 4 |
Intravenous Treprostinil |
13 |
Rapid Switch From Intravenous Epoprostenol to Intravenous Remodulin® (Treprostinil Sodium) in Patients With Stable Pulmonary Arterial Hypertension: Safety, Efficacy and Treatment Satisfaction |
Completed |
NCT00373360 |
Phase 4 |
treprostinil sodium |
14 |
An Open Label, Multi-center Study Evaluating the Safety of Long-term Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis® (Iloprost) in Subjects With Pulmonary Arterial Hypertension. |
Completed |
NCT00741819 |
Phase 4 |
Inhaled treprostinil |
15 |
An Open-label, Multicenter Study of Ambrisentan and a Phosphodiesterase Type-5 Inhibitor Combination Therapy in Subjects With Pulmonary Arterial Hypertension Who Have Demonstrated a Sub-Optimal Response to a Phosphodiesterase Type-5 Inhibitor |
Completed |
NCT00617305 |
Phase 4 |
Ambrisentan;Placebo;Sildenafil;Tadalafil |
16 |
An Open-label Extension of Study AC-066A401 Investigating the Safety and Tolerability of ACT-385781A Compared to Flolan® in Injectable Prostanoid Treatment-naïve Patients With Pulmonary Arterial Hypertension (PAH) |
Completed |
NCT01105117 |
Phase 4 |
ACT-385781A (Actelion Epoprostenol);Flolan® |
17 |
A Multicenter, Randomized, Parallel Placebo-Controlled Study of the Safety and Efficacy of Subcutaneous Remodulin® Therapy After Transition From Flolan® in Patients With Pulmonary Arterial Hypertension |
Completed |
NCT00058929 |
Phase 4 |
treprostinil sodium |
18 |
A Phase IV, Open-label, Randomized, Multicenter Study of the Safety, Tolerability,and Pharmacokinetics of ACT- 385781A Compared to Flolan® in Injectable Prostanoid Treatment-naïve Patients With Pulmonary Arterial Hypertension (PAH) |
Completed |
NCT01105091 |
Phase 4 |
ACT-385781A (Actelion Epoprostenol);Flolan® |
19 |
A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis |
Completed |
NCT01042158 |
Phase 4 |
tadalafil and ambrisentan upfront combination therapy |
20 |
A Prospective, Multicenter, Single-arm, Open-label, Phase 4 Study to Evaluate the Effects of Macitentan on Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension Assessed by Cardiac Magnetic Resonance Imaging |
Completed |
NCT02310672 |
Phase 4 |
Macitentan |
21 |
Open Label, Non Comparative Study to Investigate the Effect of Bosentan on Pulmonary Artery Remodelling in Pulmonary Arterial Hypertension (PAH). |
Completed |
NCT00595049 |
Phase 4 |
bosentan |
22 |
Therapy of Pulmonary Arterial Hypertension (PAH) With Bosentan in Patients With Eisenmenger Syndrome |
Completed |
NCT00266162 |
Phase 4 |
Bosentan administration |
23 |
A Multinational, Multicentre, Randomized, Double-blind Study To Assess The Efficacy And Safety Of Oral Sildenafil 20mg Tid Or Placebo When Added To Bosentan In The Treatment Of Subjects, Aged 18 Years And Above, With Pulmonary Arterial Hypertension (Pah) |
Completed |
NCT00323297 |
Phase 4 |
Bosentan;Sildenafil Citrate |
24 |
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Tracleer (Bosentan) on Oxygen Saturation and Cardiac Hemodynamics in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger Physiology |
Completed |
NCT00317486 |
Phase 4 |
bosentan |
25 |
Effects of Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Morbidity and Mortality in Symptomatic Patients With Pulmonary Arterial Hypertension - A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Prospective, Event Driven Phase IV Study |
Completed |
NCT00303459 |
Phase 4 |
bosentan;placebo |
26 |
A Multi-Center, Open-Label Extension Study to Protocol AC-052-405 to Evaluate the Safety and Efficacy of Tracleer (Bosentan) in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger Physiology |
Completed |
NCT00367770 |
Phase 4 |
Tracleer® |
27 |
A Phase 3, Multi-center, Open-label Study To Investigate Safety, Efficacy, And Tolerability Of Sildenafil Citrate In Pediatric Patients With Pulmonary Arterial Hypertension |
Completed |
NCT01642407 |
Phase 4 |
Sildenafil |
28 |
A Single-arm, Open Label Study Evaluating the Impact on Lifestyle of a New Thermo Stable Formulation of FLOLAN® in Subjects With Pulmonary Arterial Hypertension (PAH). (FLOLAN® is a Registered Trademark of the GlaxoSmithKline Group of Companies.) |
Completed |
NCT01462565 |
Phase 4 |
current marketed FLOLAN (epoprostenol sodium);new thermo stable formulation of epoprostenol sodium |
29 |
A 16 Week, Open Label, Multi-centre, Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of a Rapid Dose Titration Regimen of Subcutaneous Remodulin® Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) |
Completed |
NCT02847260 |
Phase 4 |
Remodulin |
30 |
Efficacy of Beraprost in Lowering Pulmonary Arterial Pressure in Pulmonary Arterial Hypertension Children Associated With Left to Right Shunt Congenital Heart Defect |
Completed |
NCT03431649 |
Phase 4 |
Beraprost Sodium;Sildenafil Citrate |
31 |
CombinatiON Up-FRON t Therapy for PAH - A Phase 4, Randomized, Multicenter Study of Inhaled Treprostinil in Treatment naïve Pulmonary Arterial Hypertension Patients Starting on Tadalafil |
Completed |
NCT01305252 |
Phase 4 |
treprostinil inhalations;tadalafil |
32 |
A Phase IV, Prospective, Single-Arm, Open-Label Study to Measure Outcomes in Patients With Pulmonary Arterial Hypertension Not on Active Treatment |
Completed |
NCT02191137 |
Phase 4 |
Riociguat (Adempas, BAY63-2521) |
33 |
A Prospective, Randomized, International, Multicenter, Double-arm, Controlled, Open-label Study of Riociguat in Patients With Pulmonary Arterial Hypertension (PAH) Who Are on a Stable Dose of Phosphodiesterase-5 Inhibitors (PDE-5i) With or Without Endothelin Receptor Antagonist (ERA), But Not at Treatment Goal |
Completed |
NCT02891850 |
Phase 4 |
Riociguat (Adempas, BAY63-2521);Sildenafil;Tadalafil |
34 |
An Open-Label Uncontrolled Study of the Safety and Efficacy of Ambrisentan in Patients With Exercise Induced Pulmonary Arterial Hypertension |
Completed |
NCT01338636 |
Phase 4 |
Ambrisentan |
35 |
EXPEDITE: A 16-Week, Multicenter, Open-label Study of Remodulin Induction Followed by Orenitram Optimization in Subjects With Pulmonary Arterial Hypertension |
Completed |
NCT03497689 |
Phase 4 |
Intravenous/Subcutaneous Treprostinil; Oral Treprostinil |
36 |
Management of Acute Pulmonary Hypertensive Crisis in Children With Known Pulmonary Arterial Hypertension |
Completed |
NCT05439460 |
Phase 4 |
Phenylephrine;Epinephrine;Arginine Vasopressin |
37 |
COMPASS 3: An Open-label, Multi-Center Study Employing a Targeted 6-Minute Walk Test (6-MWT) Distance Threshold Approach to Guide Bosentan-Based Therapy and to Assess the Utility of Magnetic Resonance Imaging (MRI) on Cardiac Remodeling |
Completed |
NCT00433329 |
Phase 4 |
Bosentan;Sildenafil |
38 |
Inhaled Iloprost for Sarcoidosis Associated Pulmonary Hypertension |
Completed |
NCT00403650 |
Phase 4 |
Iloprost |
39 |
Transition From Parenteral Prostanoids to Inhaled Treprostinil |
Completed |
NCT01268553 |
Phase 4 |
Treprostinil |
40 |
Safely Change From Bosentan to Ambrisentan in Pulmonary Hypertension |
Completed |
NCT01330108 |
Phase 4 |
ambrisentan |
41 |
Phase IV Study of Chronic Infusional Epoprostenol for Severe Primary Pulmonary Hypertension |
Completed |
NCT00004754 |
Phase 4 |
epoprostenol |
42 |
Effects of Treprostinil on Right Ventricular Structure and Function in Patients With Pulmonary Arterial Hypertension |
Recruiting |
NCT03835676 |
Phase 4 |
Treprostinil |
43 |
An Open-label, Multi-national, Multi-center, Single-arm, Uncontrolled, Long-term Extension Study of Orally Administered Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH) Who Received Riociguat in a Bayer Clinical Trial |
Recruiting |
NCT02759419 |
Phase 4 |
Adempas (Riociguat, BAY63-2521) |
44 |
A Phase 4, Prospective, Multicenter, Single-Arm Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Patients With Pulmonary Arterial Hypertension: ARTISAN (Afterload Reduction To Improve Right Ventricular Structure And FuNction) |
Recruiting |
NCT05203510 |
Phase 4 |
Parenteral Treprostinil;Oral Treprostinil |
45 |
A Prospective, Multicenter, Single-Arm, Open-Label, Phase 4 Study of the Effects of Selexipag on Right Ventricular Remodeling in Pulmonary Arterial Hypertension Assessed by Cardiac Magnetic Resonance Imaging |
Recruiting |
NCT04435782 |
Phase 4 |
JNJ-67896049 |
46 |
An Open-label, Prospective, Single Centre Study of the Effects of Riociguat on RIght VEntricular Size and Function in Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension |
Recruiting |
NCT04954742 |
Phase 4 |
Riociguat |
47 |
Spironolactone Therapy in Chronic Stable Right HF Trial |
Recruiting |
NCT03344159 |
Phase 4 |
Spironolactone;Placebo |
48 |
An International, Non-Drug Interventional, Real-world Cohort of PAH Patients Newly Initiating PAH Therapy With Guideline-directed Assessments of Disease Severity |
Recruiting |
NCT04955990 |
Phase 4 |
PAH Therapies |
49 |
A MULTINATIONAL, MULTICENTER STUDY TO ASSESS THE EFFECTS OF ORAL SILDENAFIL ON MORTALITY IN ADULTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) |
Terminated |
NCT02060487 |
Phase 4 |
sildenafil citrate |
50 |
A MULTINATIONAL, MULTICENTRE, RANDOMIZED, PARALLEL GROUP, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF 1MG, 5MG AND 20 MG TID OF ORAL SILDENAFIL IN THE TREATMENT OF SUBJECTS AGED 18 YEARS AND OVER WITH PULMONARY ARTERIAL HYPERTENSION (PAH) |
Terminated |
NCT00430716 |
Phase 4 |
Sildenafil citrate |
|